Drug
Feladilimab clinical trials
- studies test it
- 4
- open now
- 0
- in phase 3
- 0
- first study started
- 2019
How studies write it
Studies that test it under each name
Name
Development codes
Studies by the year they started
4 studies that test it; most in 2019 (3)
| Year | Studies |
|---|---|
| 2019 | 3 |
| 2021 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 1
- Phase 2
- 4
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 4 · Other 0
Often tested with
Tested in the same studies.
Ipilimumab (2) · Belantamab mafodotin (1) · Docetaxel (1) · Belrestotug (1) · Dostarlimab (1) · Nelistotug (1)
Studies
Open first, then newest update. How each study uses feladilimab is read from its arms, and is right about nine times in ten.
Testing it · 4
- Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Feladilimab (GSK3359609) in Participants With RRMMActive, not recruitingPhase 1/2GlaxoSmithKlineNCT07217119Written as Feladilimab
- Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC)CompletedPhase 2GlaxoSmithKlineNCT03739710Written as Feladilimab
- Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 2TerminatedPhase 2GlaxoSmithKlineNCT06790303Written as Feladilimab
- Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 1CompletedPhase 2GlaxoSmithKlineNCT05553808Written as Feladilimab
Given in every arm · 6 — feladilimab is usual care beside what is tested
- Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)Active, not recruitingPhase 1/2GlaxoSmithKlineNCT04126200Written as Feladilimab
- Dose Escalation and Expansion Study of GSK3359609 in Participants With Selected Advanced Solid Tumors (INDUCE-1)CompletedPhase 1GlaxoSmithKlineNCT02723955Written as feladilimab (GSK3359609)
- Study of GSK3359609 With Pembrolizumab and 5-fluorouracil (5-FU)-Platinum Chemotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaTerminatedPhase 3GlaxoSmithKlineNCT04428333Written as Feladilimab
- Study of a Combination of GSK1795091 and Immunotherapies in Subjects With Advanced Solid TumorsCompletedPhase 1GlaxoSmithKlineNCT03447314Written as GSK3359609
- GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid TumorsCompletedPhase 1/2GlaxoSmithKlineNCT03693612Written as feladilimab
- Study of GSK3359609 and Pembrolizumab in Programmed Death Receptor 1-ligand 1 (PD-L1) Positive Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaTerminatedPhase 3GlaxoSmithKlineNCT04128696Written as feladilimab
Codes
What other systems call feladilimab · ClinicalTrials.gg INT017500
- UNII (FDA) OUP4QB2A3RFELADILIMABOne source FDA
- NCI Thesaurus C126804FeladilimabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | OUP4QB2A3R | FELADILIMAB | One source FDA |
| NCI Thesaurus | C126804 | Feladilimab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.